STOCKS TELEGRAPH

Tag: Nasdaq: TNXP

  • 3 Stocks Getting Market Buzz: Merit Medical Systems (MMSI), Tonix Pharmaceuticals (TNXP), Cardiol Therapeutics (CRDL)

    3 Stocks Getting Market Buzz: Merit Medical Systems (MMSI), Tonix Pharmaceuticals (TNXP), Cardiol Therapeutics (CRDL)

    Current market trends highlight a move toward more disciplined investment strategies, with a focus on firms that offer clear visibility into future performance. In biotech, this is amplified by the impact of clinical developments and regulatory updates, which frequently drive sharp movements in share prices.

    Merit Medical Systems, Inc (MMSI)

    Merit Medical Systems, Inc (NASDAQ: MMSI) opened the trading on April 16, 2026, with a bit cautious approach as it glided -0.89% to $70.1. During the day, the stock rose to $70.95 and sunk to $69.76. Taking a more long-term approach, MMSI posted a 52-week range of $66.34-$100.19.

    Nevertheless, stock’s Earnings Per Share (EPS) this year is 5.41%. This publicly-traded company’s shares outstanding now amounts to $59.42 million, simultaneously with a float of $58.22 million. The organization now has a market capitalization sitting at $4.18 billion.

    Tonix Pharmaceuticals Holding Corp (TNXP)

    Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) started the day on April 16, 2026, with a price decrease of -1.46% at $14.13. During the day, the stock rose to $14.52 and sunk to $13.46. Taking a more long-term approach, TNXP posted a 52-week range of $11.60-$69.97.

    It was noted that the giant of the Healthcare sector posted annual sales growth of 86.72% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 86.72%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 40.08%. This publicly-traded company’s shares outstanding now amounts to $13.41 million, simultaneously with a float of $13.40 million. The organization now has a market capitalization sitting at $189.42 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is extending its strategic reach through the development of next-generation therapies designed to address large-scale cardiovascular conditions, particularly heart failure. By advancing beyond its lead oral therapy, the company is positioning itself to capture opportunities in significantly larger markets with high unmet need.

    Market Momentum

    As of April 16, 2026, CRDL closed at $1.41, down 1.40%, with trading volume (330,690 shares) below its average of 581,219 shares—indicating lighter trading activity and short-term consolidation. With a market cap of $157.469M, the stock remains within its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.53 continues to reflect meaningful upside potential, supported by ongoing pipeline development.

    Pipeline Expansion: CRD-38

    Cardiol is developing CRD-38 as a subcutaneous therapy aimed at treating heart failure, including HFpEF. This next-generation drug is designed for more convenient dosing and broader clinical use, targeting both inflammation and fibrosis—two key drivers of heart failure progression.

    Strategic Importance

    Heart failure represents a multi-billion-dollar global market with millions of patients and limited therapies addressing inflammatory pathways. By advancing CRD-38, Cardiol is positioning itself to enter this large and underserved space, significantly expanding its long-term commercial opportunity beyond niche indications.

    Outlook

    As CRD-38 progresses toward clinical development, it has the potential to transform Cardiol’s growth profile. Success in heart failure could elevate the company from a single-asset story to a diversified cardiovascular innovator.

  • Here is why Tonix Pharmaceuticals Holding Corp. (TNXP) stock plummeted on Friday?

    TNXP stock closed Friday, July 23, 2021 at $0.98. Earlier in the morning session on Monday, TNXP shares lost 34.18% at $0.64. Tonix Pharmaceuticals Holding Corp. (TNXP) shares have fallen 35.10% over the last 12 months, and they have moved up 0.04% in the past week. Over the past three months, the stock has lost 5.77%, while over the past six months, it has shed 4.85%.

    Let’s have a brief look at its recent news and developments.

    Negative Results of Interim Analysis of Phase 3 Study of TNX-102 SL

    On July 23, 2021, Tonix Pharmaceuticals Holding Corp (TNXP)  decided to stop enrollment in the Phase 3 RALLY study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia following an unblinded, pre-planned interim analysis by the Independent Data Monitoring Committee (IDMC) of the RALLY study.

    IDMC recommended stopping the trial for futility, after the interim analysis results of the first 50% enrolled participants as TNX-102 SL is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall change from baseline in daily diary pain severity scores between those treated with TNX-102 SL 5.6 mg (2x 2.8 mg tablets) and those receiving placebo.

    TNXP New board member appointment

    Tonix Pharmaceuticals Holding Corp appointed Carolyn E. Taylor to its Board of Directors, effective as of July 16, 2021.

    TNXP Inauguration to Russell 2000® and Russell 3000® Indexes

    TNXP stock was added to the broad-market Russell 3000® index and the small-cap Russell 2000® Index, effective after the U.S. market opened on June 28, 2021, as part of the annual reconstitution of the Russell stock indexes.

    Treatment for Long COVID Syndrome

    On June 21, 2021, Tonix Pharmaceuticals Holding Corp (TNXP) announced its plans to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets) as a potential treatment for Long COVID Syndrome (Long COVID) which is now known officially as Post-Acute Sequelae of COVID-19 (PASC).

    Tonix plans to meet with the U.S. Food and Drug Administration (FDA) in the third quarter of 2021 to seek agreement on the design of a potential Phase 2 pivotal study and the overall clinical development plan to qualify TNX-102 SL as an indicated treatment for Long COVID.

    Participation in the conferences

    Tonix (TNXP) recently participated in the BIO Digital Conference which was held on June 10-11 and 14-18, 2021. The company was presented by Seth Lederman, M.D., President and Chief Executive Officer of Tonix.

    The company also participated in the Raymond James Human Health Innovation Conference which was held on June 23, 2021.

    Conclusion

    The company’s recent announcement about halting the enrolment in TNX-102 SL trials due to negative outcomes was the reason behind its significant loss on Friday. TNXP can continue to decline in the coming days as well.

  • Tonix Pharmaceuticals Holding. (TNXP) Reports Promising Phase 3 Trial Findings for cyclobenzaprine HCl tablets in Fibromyalgia

    Tonix Pharmaceuticals Holding. (TNXP) Reports Promising Phase 3 Trial Findings for cyclobenzaprine HCl tablets in Fibromyalgia

    Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biotech company, earlier announced that in the Phase 3 RELIEF trial, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) reached its pre-specified primary endpoint, substantially reducing everyday pain in fibromyalgia participants relative to placebo (p=001) (Table 1). (Table 1). TNX-102 SL is a modern non-opioid, centrally-acting analgesic that has been formulated for the treatment of Fibromyalgia and is taken once daily at bedtime. RELIEF was a 14-week TNX-102 SL 5.6 mg randomized, double-blind, placebo-controlled study in which a total of 503 patients with Fibromyalgia were randomized through 39 U.S. sites with a 1:1 ratio.

    For the first two weeks, all patients obtained one tablet of TNX-102 SL (2.8 mg) or placebo, which was improved for the remaining 12 weeks to 2 tablets of TNX-102 SL (5.6 mg) or placebo.

    Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, said, “Tonix is focused to improving the quality of life of the millions who suffer from fibromyalgia, about 90% of which are women, and the results of the RELIEF trial bringing fresh hope to this group.”

    At 5.6 mg, TNX-102 SL demonstrated highly significant and strongly positive progress in the primary endpoint of daily pain reduction and activity in the key secondary endpoints of sleep improvement and fatigue reduction. Finding a dose that balances safety and tolerability is one of the greatest challenges in clinical trials. In the RELIEF study, the company gladly found the consistent effects of TNX-102 SL 5.6 mg on both the primary endpoint of daily pain and the tolerability of this dose.